Shandong Xinhua Pharmaceutical Shandong Xinhua Pharmaceutical (山东新华制药股份有限公司) is a healthcare company that produces antipyretic and analgesic drugs. | ![]() Catalent Catalent is a company that develops and manufactures solutions for drugs, protein-based biologics, cell and gene therapies, vaccines, and consumer health products. | PPD PPD (Pharmaceutical Product Development) is a company that provides drug development and laboratory solutions. | WuXi Biologics WuXi Biologics (药明生物) is a company operating as an open-access technology platform for biologics drug development. | ||
Founding Date | Founding Date 1943 | Founding Date 2007 | Founding Date 1985 | Founding Date 1993 | Founding Date 2010 |
Type | Type Public | Type Subsidiary | Type Subsidiary | Type Public | Type Public |
Tags | |||||
Locations | Locations Zibo, CN HQ | Locations Bridgewater, US HQ Buenos Aires, AR Bruxelles, BE Charleroi, BE Charleroi, BE Charleroi, BE Indaiatuba, BR see more | Locations Wilmington, US HQ Buenos Aires, AR Melbourne, AU Brussels, BE Zaventem, BE São Paulo, BR São Paulo, BR see more | Locations Hamburg, DE HQ Lyon, FR Toulouse, FR Göttingen, DE Halle (Westfalen), DE Köln, DE Munich, DE see more | Locations Wuxi, CN HQ George Town, KY Wuppertal, DE Hong Kong, HK Dundalk, IE Cranbury, US King Of Prussia, US |
Employees | Employees 7,296 | Employees 12,6955% increase | Employees 24,5842% decrease | Employees 4,766 | Employees 12,575 |
Valuation ($) | Valuation ($) 1.2 b | Valuation ($) N/A | Valuation ($) N/A | Valuation ($) 1.4 b | Valuation ($) N/A |
Financial | |||||
Revenue (est.) | Revenue (est.) ¥8.6b (FY, 2025) | Revenue (est.) $4.4b (FY, 2024) | Revenue (est.) $4.7b (FY, 2020) | Revenue (est.) €788.4m (FY, 2025) | Revenue (est.) ¥21.8b (FY, 2025) |
Cost of goods | Cost of goods ¥7.1b (FY, 2025) | Cost of goods $3.4b (FY, 2024) | Cost of goods $1.7b (FY, 2020) | Cost of goods €622.9m (FY, 2025) | Cost of goods ¥10b (FY, 2025) |
Gross profit | Gross profit ¥1.6b (FY, 2025) | Gross profit $953m (FY, 2024) | Gross profit $3b (FY, 2020) | Gross profit €231.1m (FY, 2025) | Gross profit ¥12b (FY, 2025) |
Net income | Net income ¥306.3m (FY, 2025) | Net income ($1b) (FY, 2024) | Net income $160.6m (FY, 2020) | Net income (€103.5m) (FY, 2025) | Net income ¥5.7b (FY, 2025) |
Operating ⚠ | |||||
Backlog | Backlog N/A | Backlog $2.5b (FY, 2023) | Backlog $9.5b (Q3, 2021) | Backlog N/A | Backlog $18.5b (H1, 2022) |
Countries | Countries N/A | Countries 80 (FY, 2023) | Countries 46 (FY, 2020) | Countries N/A | Countries N/A |
Customers | Customers N/A | Customers 1.2 k (FY, 2023) | Customers N/A | Customers 781 (FY, 2023) | Customers N/A |
Products | Products N/A | Products 8 k (FY, 2023) | Products N/A | Products 140 (FY, 2023) | Products N/A |
Funding | |||||
Total funding raised | Total funding raised N/A | Total funding raised $ 650m | Total funding raised N/A | Total funding raised $ 993.6m | Total funding raised N/A |

Catalent is a company that develops and manufactures solutions for drugs, protein-based biologics, cell and gene therapies, vaccines, and consumer health products.
View companyPPD (Pharmaceutical Product Development) is a company that provides drug development and laboratory solutions.
View companyEvotec is a biotechnology company that provides drug discovery and development services.
View companyWuXi Biologics (药明生物) is a company operating as an open-access technology platform for biologics drug development.
View company